Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Apply
ACTengine® IMA203 & Nivolumab
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step